CYP46A1 Activation by Efavirenz Leads to Behavioral Improvement without Significant Changes in Amyloid Plaque Load in the Brain of 5XFAD Mice

Efavirenz, the FDA-approved anti-retroviral medication, is evaluated in the clinical trial in patients with mild cognitive impairment or early dementia due to Alzheimer’s disease. Efavirenz is assessed for activation of cytochrome P450 46A1 (CYP46A1), a CNS-specific enzyme that converts cholesterol...

Full description

Bibliographic Details
Published in:Neurotherapeutics : The Journal of the American Society for Experimental NeuroTherapeutics, Vol. 16, No. 3 (2019), p. 710-724
Main Author: Petrov, M.
Other Involved Persons: Lam, Morrie ; Mast, Natalia ; Moon, Jean ; Li, Yong ; Maxfield, Erin ; Pikuleva, A.
Format: electronic Article
Language:English
ISSN:1878-7479
Physical Description:Online-Ressource
DOI:10.1007/s13311-019-00737-0
Subjects:
Other Editions:Show all 2 Editions
QR Code: Show QR Code